Entecavir
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-ENTECAVIR |
|---|---|
| Type | Drug |
| Aliases | BaracludeЕнтекавір |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Nucleoside HBV polymerase inhibitor |
|---|---|
| Mechanism | Guanosine analog; inhibits HBV reverse transcriptase / polymerase activity, suppressing viral replication. |
| Typical dosing | 0.5 mg PO daily (treatment-naive); 1 mg PO daily (lamivudine-experienced) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Used as HBV reactivation prophylaxis in HBsAg+ or anti-HBc+ patients receiving rituximab/obinutuzumab or chemotherapy. Continue for at least 12 months after completing immunosuppressive therapy.
Used By
Supportive Care
SUP-HBV-PROPHYLAXIS- HBV reactivation prophylaxis with entecavir